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Abstract
Background: The effectiveness of classic standard triple therapy regimen of helicobacter pylori (H. pylori)
eradication has decreased to unacceptably low levels, largely related to development of resistance to metronida-
zole and clarithromycin. Thus successful eradication of H. pylori infections remains challenging. Therefore
alternative treatments with superior effectiveness and safety should be designed and appropriately tested in all
areas depending on the native resistance patterns. Furazolidone has been used successfully in eradication regimens
previously and regimens containing furazolidone may be an ideal regimen.
Methods: H. pylori infected patients with proven gastric or duodenal ulcers and /or gastric or duodenal erosions
at Imam Khomeini Hospital in Sari/Northern Iran, were randomly allocated into three groups: group A (OABF)
with furazolidone (F) (200 mg bid.), group B (OABM-F) metronidazole (M) (500 mg bid.) for the first five days,
followed by furazolidone (F) (200 mg bid.) for the second five days and group C (OAF) with furazolidone (F)
(200 mg tid.). Omeprazole (O) (20 mg bid.) and amoxicillin (A) (1000 mg bid.) were given in all groups; bismuth
(B) (240 mg bid.) was prescribed in groups A & B. Duration of all eradication regimens were ten days. Eight
weeks after treatment, a 14C-urea breath test was performed for evaluation of H. pylori eradication.
Results: A total of 372 patients were enrolled in three groups randomly (124 patients in each group); 120 (97%)
patients in group A (OABF), 120 (97%) in group B (OABM-F) and 116 (93%) in group C (OAF) completed the
study. The intention-to-treat eradication rates were 83.7% (95% CI= 77.3–90.4), 79.8% (95% CI= 72.6–87), and
84.6% (95% CI= 78.2–91.1) and per-protocol eradication rates were 86.6% (95% CI= 80.5–92.8), 82.5% (95%
CI= 75.6–89.4), and 90.5% (95% CI= 85.1–95.9) for groups OABF, OABM-F, and OAF, respectively. No statis-
tical significant differences were found in case of severe drug adverse effects between the above mentioned three
groups (p> 0.05). The most common side effects, namely nausea and fever, occurred in all groups, but more
frequently in group C (OAF) (p< 0.05).
Conclusion: In developing countries such as Iran, furazolidone-based regimens can substitute clarithromycin-
based regimens for H. pylori eradication because of a very low level of resistance, low cost and high effective-
ness. Considering per-protocol eradication rate of ten days OAF regimen, and the acceptable limit of ninety
percent, we recommend this regimen in developing countries such as Iran to be substituted of classic standard
triple therapy. In order to minimize rare serious adverse effects, one week high dose OAF regimen should be
taken into consideration in other studies.
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Introduction
Helicobacter pylori (H. pylori) is one of
the most prevalent infectious agent in the
world and approximately half of the world's
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population infected with this organism,
predominantly live in Asia. It has a major
role in the peptic ulcer disease, gastric ade-
nocarcinoma, maltoma, chronic gastritis
and atrophic gastritis. Its prevalence in pa-
tients over 25 years of age has been report-
ed more than 90% in Iran. The ideal treat-
ment for H. pylori infection is a regimen
that is well tolerated, with minor side ef-
fects(<5%), eradication rate by “per-
protocol” and “intention–to-treat” method
is more than 90-95% and 80%, respectively
(1-3). A more successful regimen should be
studied in other regions (4). Although vari-
ous regimens for treatment of H. pylori has
been introduced; but the optimal regimen
has not been defined yet (5). The classic
standard triple drug regimen in American
and European countries led to increased
resistance to antibiotics such as metronida-
zole and clarithromycin, and reduced eradi-
cation rate. Therefore we needed a regimen
being able to overcome these antibiotic re-
sistance. Then, a sequential regimen (10
days) was used and became the preferred
regimen as the first-line therapy previously
(3,6,7). Sequential regimen is still a good
treatment but not ideal, because eradication
rate decreased in some areas due to dual
drug resistanceto metronidazole and clar-
ithromycin.  It is probably that the concom-
itant quadruple regimen (bismuth or non-
bismuth containing) or hybrid regimen are
more effective, due to overcoming dual
drug resistance. Recently sequential regi-
men is conducted and approved in Northern
Iran (7,8).
In Iran, during the years 2003-2011, clar-
ithromycin and metronidazole resistance
increased markedly from 1.2% to 30-34%
and from 32% to 78%, respectively, while
there was only a slight increase in furazoli-
done resistance (0% to 4.5%)(9-14). In de-
veloping countries such as Iran, furazoli-
done, due to low cost and drug resistance
and high effectiveness, may be a better al-
ternative to clarithromycin or metronida-
zole in the first-line regimen of eradication
(15,16). Meanwhile, it is recommended to
evaluate more regimens containing furazol-
idone to find the proper dose of furazoli-
done (15). It seems that regimens with less
than 14 days duration of treatment are not
very effective in Iran (9,17) . However, the
arrangement of a regimen is not fixed and
the eradication rate of that regimen can be
increased through changing the type of the
drugs, dose of the drugs, interval between
doses and duration of treatment (4). Re-
sistance of H. pylori to clarithromycin and
metronidazole in recent years is reported in
the world and Iran. The study originality
underlies the reduced effectiveness of some
regimens containing clarithromycin, the
high cost of some antibiotics such as clar-
ithromycin and ofloxacin in developing
countries, recommendation of some re-
searchers to do more regional studies on
regimens containing furazolidone and the
results obtained especially in developing
countries (3,6,7,16). We designed this
study to compare the effectiveness and
safety of quadruple and triple 10-day regi-
mens containing furazolidone for H. pylori
eradication in all patients with H. pylori
infected gastric or duodenal ulcer or ero-
sions referred to the clinic/office of gastro-
enterologists or endoscopy unit of Imam
Khomeini Hospital in Sari, Iran.
Methods
Data
This clinical trial was performed on 372
patients at Imam Khomeini Hospital in Sa-
ri/Northern Iran. Participants were patients’
whose duodenal ulcer, gastric ulcer and/or
erosions was diagnosed by endoscopy and
H. pylori infection was detected by rapid
urease test (RUT, Shim-anzym,Tehran,
Iran) or histological Geimsa staining on
biopsied specimens from antrum and body
during endoscopy.  We considered the dif-
ference of about16% in eradication rate of
these three regimens (according to alpha=
0.05 and beta= 0.2) and based on pilot
study and statistical calculations, at least a
total number of 372 patients were chosen to
participate in this study (at least 124 pa-
tients in each group). Exclusion criteria
were; age less than 18 years, pregnancy or
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lactation, history of previous H. pylori
eradication, taking antibiotics  and/or  non-
steroid anti-inflammatory drugs (NSAID)
or bismuth during the previous 4 weeks,
concomitant use of alcohol, anticoagulant,
monoamine oxidase inhibitors (MAOIs),
sympathomimetics and/or corticosteroid,
history of gastric surgery, known case of
neoplasms and severe underlying disease
such as; liver, renal, pulmonary or cardiac
disease, G6PD deficiency and history of
drug allergy to any mentioned medication
in this study .
The aim and nature of the study was fully
explained for patients and informed consent
was obtained. This study was accepted in
the Ethics Committee of Mazandaran Uni-
versity of Medical Sciences (Code number:
91-139), and the proposal was also regis-
tered in Iranian Registry of Clinical Trials
(IRCT code: 2013120715701N1).We used
permuted (computer-generated) random-
ized blocks for randomization and each
group was treated with one of the three fol-
lowing regimens:
Group A (OABF): Omeprazole (20mg),
Amoxicillin (1000mg), Bismuth (240mg),
Furazolidone (200mg); all prescribed twice
a day for ten days.
Group B (OABM-F): Omeprazole
(20mg), Amoxicillin (1000mg) and Bis-
muth (240 mg), all prescribed twice a day
for the whole ten days. Metronidazole
(500mg twice a day) during the first 5 days
and Furazolidone (200mg twice a day) dur-
ing the second remaining 5 days were pre-
scribed.
Group C (OAF): Omeprazole (20 mg),
Amoxicillin (1000mg), twice a day and
Furazolidone (200mg) three times a day, all
prescribed for ten days.
Ulcer characteristics (location, diameter
in mm, number and depth) and the presence
or absence of bulb deformity were recorded
in each patient. In addition to demographic
data, history of gastrointestinal bleeding
and current smoking were recorded in each
patient. All patients received one of three
above treatments randomly. In addition, all
patients were advised to avoid consumption
of thyramine-containing foods and MAOI
medications during the ten days of treat-
ment (List of thyramine-containing foods
and MAOI medications delivered to pa-
tients by patient’s informative sheet). The
patients were given both oral and written
instructions about the significance of taking
the medications regularly and were sug-
gested not to stop medication in the event
of mild to moderate side effects. Patients
recorded adverse effects of drugs on a daily
basis in their informative sheets and were
advised to call the physician or senior phy-
sician in charge of study in case of any
problematic or severe adverse effects. Pa-
tients referred to the clinic 2, 6 and 12
weeks after starting the treatment.
The patients were asked about their com-
pliance to treatment, number of remaining
pills (if any), and presence and severity of
side effects verbally and/or written in pa-
tient’s informative sheet, 2 weeks after
starting treatment. The gathered data trans-
formed to data gathering sheets for analy-
sis. The severity of side effects was classi-
fied as 0= no side effect; 1= mild side ef-
fects (no limitation in daily activities); 2=
moderate (partial limitation in daily activi-
ties); and 3= severe (profound limitation in
daily activities). Medications were discon-
tinued if any intolerable adverse event oc-
curred. The compliance to treatment was
considered to be excellent if the patient had
consumed more than 80% of prescribed
medications, acceptable or good for 60–
80% medication consumption, and poor for
< 60%. Omeprazole was continued 4 weeks
after staring treatment. Next, no antibiotics
or omeprazole was taken for 8 weeks.
Twelve weeks after starting the treatment,
H. pylori eradication was assessed by 14 C-
urea breath test (UBT). To perform UBT,
patients swallowed 37kBq (lCi) encapsulat-
ed 14 C-labeled urea composition (Helicap
Institute of Isotopes, Budapest, Hungary)
with water. After 10 minutes, patients ex-
haled into a cartridge (Heliprobe breath
card, Kibion Uppsala, Sweden) until the
indicator of the card changed from orange
to yellow. The cards were inserted into a
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Geiger–Muller counter (Heliprobe Analys-
er, Kibion AB), and radioactivity of sam-
ples was automatically measured after 250
seconds. Based on radioactivity, as count
per minute (cpm), counts more than 50cpm
were considered infected with H. pylori
(Positive UBT) and count less than 25cpm
were considered H. pylori eradication. The
borderline UBT values were considered as
eradicated.
Statistical Analysis
Data were analyzed using SPSS 16. Dis-
criptive statistics are reported as mean ±
SD. We used ANOVA for comparing
means between three groups and Chi square
or Fisher exact tests for comparing propor-
tion between groups and p< 0.05 was con-
sidered statistically significant.
The statistician analyzer of ultimate re-
sults was unsighted to the assignment of
patients.
To calculate the intention-to-treat (ITT)
eradication rates, we included everyone
who entered the study was considered, and
to calculate per-protocol (PP) eradication
rates, only those who completed the entire
protocol with more than 90% compliance to
treatment and returned for final test of erad-
ication.
Results
Three hundred and seventy two patients
were enrolled in this study; 47.3% (176)
were women and 52.7% (196) were men.
The mean (±SD) age of the patients was
42.28 (±.29) years (range: 18-83 years).
The mean (±SD) age of patients in three
groups were 43.7 (±13.91), 40.8 (±14.60)
and 42.3 (± 14.31), respectively.
There were not statistically significant
difference between the three groups accord-
ing to age, sex, history of gastrointestinal
bleeding, current smoking (p> 0.05) and
endoscopic findings (Table 1).
The number and types of side effects in
the three treatment groups are described in
Table 2. The most common complication
was fever and nausea which were signifi-
cantly higher in group C (OAF) than two
other groups.
The majority of serious side effects in
each treatment group were observed in the
second half of the treatment period: 4 of 5
patients in the regimen A (OABF); and 4 of
4 patients in the regimen B (OABM-F) and
5 of 6 patients in the regimen C (OAF).
Prevalence of mild, moderate and severe
drug adverse effects in three studied regi-
mens is described in Table 3. Also, the
number of drug withdrawal due to severe
side effects for three groups were 3, 2 and
4, respectively.
In group A (OABF) a total of 4 patients
did not complete their treatment (3 patients
due to side effects such as rash, vomiting,
diarrhea and severe orthostatic changes and
1 patient with poor compliance). In group B
(OABM-F)  a total of 4 patients did not
complete their treatment (2 patients due to
side effects such as vomiting, nausea, sever
dizziness and 1 patient with poor
Table 1. Frequency distribution of the endoscopic findings in the three groups
A(OABF)
N=124
n (%)
B(OABM-F)
N=124
n (%)
C(OAF)
N=124
n (%)
p
Gender Male 64 (53) 65 (54) 67 (58) 0.927
Female 60 (47) 59 (46) 57 (42)
Current Smoking 14(11.3) 15(12.1) 22(17.1) 0.274
History of GIB 13(10.5) 14(11.3) 15(12.1) 0.923
Endoscopic findings DU 73(58.9) 76(61.3) 77(62.1) 0.926
GU 14(11.3) 14(11.3) 12(9.7) 0.926
GU +DU 3(2.4) 3(2.4) 2(1.6) 0.926
DE 7(5.6) 9(7.3) 5(4) 0.926
GE 24(19.4) 19(15.3) 24(19.4) 0.926
GE+DE 3(2.4) 3(2.4) 4(3.2) 0.926
Ulcer size >7 mm 59(34.7) 63(37.1) 63(37.1) 0.233
Deformity of bulb 22(17.7) 23(18.6) 23(18.6) 0.974
GIB= Gasterointestinal bleeding, DU= Duodenal Ulcer, GU= Gasreric Ulcer, DE= Duodenal Erosions, GE= Gasteric Erosions
M. Mokhtare, et al.
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compliance and one lost follow-up due to
appendectomy). In group C (OAF) a total
of 8 patients did not complete their treat-
ment (4 patients due to side effects such as
severe headache, vomiting, urticaria, fever,
and severe orthostatic changes and 2 pa-
tients with poor compliance and 2 patients
lost follow-up due to MI in one 74 years
old patient and car accident in another).
Among the participants in 3 treatment
groups, 353 patients (95%) had excellent
treatment compliance (Table 4). ITT and
Table 2. The number and types of drug side effects in three treatment groups
pC(OAF)
(n)%
B (OABM-F)
(n)%
A (OABF)
(n)%
Side effects / treatment
group
.929
.348
(5)4.0
(9)7.3
(5)4.0
(4)3.2
(4)3.2
(8)6.5
Dyspepsia
Weakness
.031
.363
(21)16.9
(4)3.2
(8)6.5
(1)0.8
(13)10.5
(2)1.6
* Nausea
Vomiting
.607
.121
(1)0.8
(17) 13.7
(0)0
(8)6.5
(1)0.8
(10)8.1
Abdominal cramp
Urine orange discoloration
.411
.367
(4)3.2
(0)0
(1)0.8
(2)1.6
(3)2.4
(1)0.8
Diarrhea
Constipation
.135
.604
(0)0
(2)1.6
(0)0
(1)0.8
(2)1.6
(3)2.4
Glossitis
Anorexia
.135
.607
(2)1.6
(0)0
(0)0
(1)0.8
(0)0
(1)0.8
Bad taste
Heartburn
.367
.778
(1)0.8
(2)1.6
(0)0
(1)0.8
(2)1.6
(1)0.8
Skin rash
Urticaria
.005
.778
(8)6.5
(2)1.6
(0)0
(1)0.8
(2)1.6
(1)0.8
Drug Fever*
Arthralgia
.369(0)0(0)0(1)0.8Bloating
.176
.291
(14)11.3
(8)6.5
(6)4.8
(3)2.4
(10)8.1
(5)4.0
Dizziness
Orthostatic changes
.135
.607
(0)0
(1)0.8
(2)1.6
(1)0.8
(0)0
(0)0
Itching
Chest pain
.137(6)4.8(1)0.8(6)4.8Headache
* p<0.05
Table 3. Prevalence of mild, moderate and severe drug adverse effects of three treatment groups
Severity of side
effects
Group A (OABF)
n (%)
Group B (OABM-F)
n (%)
Group C (OAF)
n (%)
p
Mild 41 (33.1) 30 (24.2) 37 (29.8)
Moderate side effects 2 (1.6) 2(1.6) 18(14.5)
Severe* 5(4) 4(3.2) 6(4.8) 0.812
*P value has been calculated for the incidence of severe side effects among three groups versus others
Table 4. Compliance in three treatment regimens
Compliance rate/
medical group
Group A(OABF)
n(%)
Group B (OABM-F)
n(%)
Group C(OAF)
n (%)
p
High (> 80% of drugs) 120 (96.7) 120(96.7) 116(93.5) 0.089
Acceptable (60-80% of drugs ) 3(2.4) 2(1.6) 5(4.0)
Poor (< 60% of drugs) 1(0.8) 2(1.6) 3(2.4)
*P value has been calculated for the high compliance in three groups versus others
Table 5. Intention-to-treat and per-protocol eradication rates in three treatment regimens
Total enrolled
Patients (n=372)
Group A(OABF)
(n=124)
Group B(OABM-F)
(n=124)
Group C(OAF)
(n=124)
p
Number of patients
who have consumed
>80% of drugs
120 120 116
ITT* eradication rate
with 95% CI (n=372)
83.7% (104/124)
(95%CI=77.3-90.4)
79.8% (99/124)
(95%CI=72.6-87.0)
84.6%(105/124)
(95%CI=78.2-91.1)
0.557
PP* eradication rate
with 95% CI(n=356)
86.6% (104/120)-
(95%CI=80.5-92.8)
82.5% (99/120)
(95%CI=75.6-89.4)
90.5%(105/116)-
(95%CI=85.1-95.5)
0.197
The cure rates was higher in treatment regimen C(OAF), but in general, the differences were not statistically significant (p=0.197,
p=0.557, respectively for PP and ITT) and therefore, as far as helicobacter pylori eradication level is considered, the treatment regimen
C(OAF) is in Grade B (good), and treatment regimen B (OABM-F)  is in Grade D (poor) and treatment regimen A(OABF) is in Grade
C (moderate or acceptable).
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PP eradication rates are shown in Table 5.
The algorithm of patients presented in
study is shown in Fig. 1.
Discussion
Although various treatment regimens
have been introduced to treat H. pylori, but
an ideal treatment regimen has not yet been
defined. The most common regimen intro-
duced during the last two decades, is a two
weeks triple clarithromycin-based treat-
ment with eradication rates of 75% -90% in
developed countries; currently, these eradi-
cation rates reached to 75-80.5% (3,5,18).
However, eradication rate with this regimen
in developing countries is much lower than
in developed countries. Reasons for the dif-
ference in eradication rate in the geograph-
ical area, covers a wide range of difference
in pathogenic strains of H. pylori, antibiotic
resistance pattern, type and duration of
treatment and pharmacological drug me-
tabolism (19). In Iran, eradication rate of
triple therapy is less than 60% (16).
Fig. 1. Eradication rate based on intention-to-treat and per-portocol analyzes
M. Mokhtare, et al.
7MJIRI, Vol. 29.195. 6 April 2015 http://mjiri.iums.ac.ir
Also, the rate of metronidazole resistance
has been increased in many countries.
However, this high resistance was in vitro,
and the drug has been relatively effective in
clinical trials (20,21). North American and
European institutions recommended clar-
ithromycin as a good substitute for metro-
nidazole. However, this drug may not be an
appropriate option in developing countries,
such as Iran, due to the increase of drug-
resistant strains and its high cost (17).
Evaluation of eradication regimens in Iran
showed more toxic and special species that
do not have a good response to the usual
regimens in developed countries (22).
Sequential clarithromycin-based regimen
as an effective alternative therapy for triple
therapy was introduced. Several random-
ized studies have failed to demonstrate the
superiority of this method (22,23)and the
results of this method have not been prom-
ising in Asia as well (24)which could be
due to increased resistance to clarithromy-
cin (25-27). In Iran, based on the last re-
ports, 78.6% of H. pylori are resistant to
metronidazole, 34% to clarithromycin, 10%
to amoxicillin and 4.5% to furazolidone
(11,14). Furazolidone is one of nitroimid-
azole antibiotics with a good intestinal ab-
sorption and tissue distribution (28,29). In
the last decade, this drug was effective as
the first, second and even third -line thera-
py (20,30-33).
Many researchers believe that this drug
can be an appropriate and effective alterna-
tive for clarithromycin (17). Ten to 14-day
bismuth quadruple regimen containing
furazolidone (100 mg Tid) were effective
as the first and second-line regimen in erad-
icating H. pylori. Meanwhile, in areas
where this drug is available, carrying out
more studies to find the proper dose of
furazolidone has been recommended (15).
In Iran, furazolidone, combined with
amoxicillin, bismuth, clarithromycin and a
PPI in the form of quadruple and triple
therapy, is used as the first-line therapy
with the different results based on the dose
and duration of treatment (4,17,30,34-38).
Fakheri et al in different studies on furazol-
idone- containing regimens in the north of
Iran, have shown that there was no signifi-
cant difference between bismuth and clar-
ithromycin-containing quadruple regimen
and bismuth and furazolidone-containing
quadruple regimen considering eradication
rate (34). In a study, they showed that low
doses of furazolidone (100mg bid) is not an
effective treatment, but the 14-day quadru-
ple therapy containing bismuth and furazol-
idone is associated with eradication rates of
92% (35). In another study, two 14-day
modified quadruple regimens containing
first week furazolidone while one regimen
included metronidazole and the other bis-
muth, were compared. Eradication rates
were 86.36% and 90.27%, respectively. In
addition, the side effects in the bismuth-
containing group were lower compared to
the metronidazole-containing group
(32,39).
In a recent study that compared the se-
quential and modified furazolidone-based
quadruple regimen, both of them showed
the same efficacy in eradicating H. pylori
(88.7%, 89.1%, respectively); however, due
to the high price of clarithromycin in Iran,
modified quadruple regimen is more cost-
effective (38).
Also in a study, Khatibian et al. reported
that the modified furazolidone–based quad-
ruple therapy had good effectiveness and
low cost in H. pylori eradication (36).
Meanwhile, the incidence of intolerable
side effects in furazolidone-containing reg-
imen is more than other regimens and simi-
lar to our study, adverse effects are mostly
appeared in the second half of the treatment
(32,39). Rare but serious side effects of this
drug have limited its common use. It seems
that these side effects are due to monoam-
ine oxidase inhibitory of this drug which is
occurrence is preventable by avoiding cer-
tain drugs (such as sympatomimtic and
monoamine oxidase inhibitors) and thyra-
mine containing foods such as old kinds of
cheeses (17).
However, dose and duration of furazoli-
done are effective on the incidence of side
effects (35).Shortening the duration of
Comparison of furazolidone regimen for helicobacter pylori eradication
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treatment and adding another drug such as
bismuth in combination with amoxicillin
and PPI can be a reasonable approach to
reduce the side effects and to increase the
effectiveness of furazolidone (40).
In a study in Brazil, a high dose of fura-
zolidone (600mg/day) plus tetracycline,
and a PPI was used for one week. The inci-
dence of serious side effects, patients’
compliance and the eradication rate were
7.6%, 96% and 91.8%, respectively (41).
However, other studies in Latin America
were conducted with a high dose of fura-
zolidone for 4 and 10 days which had no
serious side effects. Increasing the duration
of treatment to 10 days had no effect on the
eradication rate (42). On the other hand, in
a study in Peru, a high dose of furazolidone
(600 mg a day) plus tetracycline, and a PPI
were used for one week, the severe side
effect was 15% and eradication rate was
75% (32). Dual therapy with low dose of
furazolidone and omeprazole was used for
one week in a Latin American country
which was stopped in the middle course of
treatment due to low eradication rate
(50%), though the side effect was mild
(28).
In this study, we aimed at: shortening
treatment duration -although it seems to
reduce regimen efficacy-and examining the
rate of eradication, patient compliance and
drug side effects in regimens containing
high dose of furazolidone for the first time
in Iran. The eradication rate in high-dose
OAF regimen was higher than the other
two quadruple regimens (PP= 90.5%, ITT=
84.6% compared with the PP= 82.5% and
ITT= 79.8% in OABM-F regimen and PP=
86.6% and ITT=83.7% in OABF regimen).
However, the difference was not statistical-
ly significant. It seems that increasing the
dose of drug is more effective than adding
another drug such as bismuth to the regi-
men. On the other hand, 10-days OABM-F
regimen had an eradication rate of 91.3% in
a recent study conducted in Iran (30),
whereas in our study the eradication rate
was 82.5%. It seems that the difference in
eradication rate is related to the factors
such as differences in pathogenic strains of
H. pylori, antibiotic resistance pattern and
pharmacological differences in drug me-
tabolism in our area.
Reducing the duration of therapy in
OABF regimen from 14 to 10 days causes
the eradication rate to be decreased from
92% to 86.6%, still within acceptable erad-
ication rate, and the rate of severe side ef-
fects decreased from 20.4% to 4% (35).
In our study severe drug side effects was
less than 5% in each group, and the overall
compliance rate was 94.9%, the lowest
compliance rate was associated with high-
dose OAF regimen (91.1%). Therefore, it
shows that there is no significant difference
in severe adverse drug effect and compli-
ance between three groups. It seems that it
can be justified by the time we spent to in-
form patients about the importance of erad-
ication of H. Pylori and to avoid thyramine
containing foods and monoamine oxidase
inhibitor drugs during furazolidone con-
sumption. Interestingly, in high dose fura-
zolidone-containing regimen for the first
time in Iran, the results of eradication (PP=
90.5% and ITT= 84.6%), the incidence of
severe side effects (4.8%) and drug compli-
ance (91.1%) were in the good level.
It seems that high doses of furazolidone
has the same effect observed with high
doses of metronidazole capable to eradicate
the resistant strains of H. pylori (40).
Conclusion
According to the findings of this study,
high price of clarithromycin and high level
of single and dual resistance to clarithro-
mycin and metronidazole in developing
countries, the 10-days high dose OAF reg-
imen is acceptable with a good effective-
ness and safety profile as the first-line
treatment regimen for H. pylori eradication.
In order to minimize rare serious adverse
effects, we recommended one week high
dose OAF regimen should be taken into
consideration in other studies.
M. Mokhtare, et al.
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